Heart drug safety trial in kids: small but important step

NCT ID NCT06149104

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the safety of the drug sacubitril/valsartan in Japanese children with heart failure. Eight children who had already been in a previous trial took the drug to see if any side effects occurred. The goal was to gather more safety information and provide the drug until a child-friendly version becomes available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacubitril/valsartan
What this could lead to: If successful, this could confirm that sacubitril/valsartan is safe for Japanese children with heart failure, supporting its use as a treatment option.
What could go wrong: This is a very small study (8 participants) focused only on safety, not effectiveness. It may not detect rare side effects or apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Novartis Investigative Site

Ōbu, Aichi-ken, 474 8710, Japan
Novartis Investigative Site

Ōmura, Nagasaki, 856-8562, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 113 8655, Japan
Novartis Investigative Site

Setagaya-ku, Tokyo, 157-8535, Japan
Novartis Investigative Site

Saitama, 330 8777, Japan
Novartis Investigative Site

Toyama, 930-0194, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.